Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns

• Published in: Journal of clinical oncology Vol. 38; no. 15_suppl; p. 3625
• Main Authors: Nusrat, Maliha, Roszik, Jason, Holla, Vijaykumar, Cai, Tiantian, Hong, Meiyue, Coker, Oluwadara, Johnson, Benny, Rodon Ahnert, Jordi, Janku, Filip, Kopetz, Scott, Shaw, Kenna Rael, Meric-Bernstam, Funda, Hong, David S.
• Format: Journal Article
• Language: English; Japanese
• Published: 20.05.2020

Abstract only 3625 Background: Oncogenic KRAS mut drive cancers and confer therapeutic resistance by activating MAPK signaling. Inhibiting KRAS has been elusive until the recent promising phase I trials with KRAS G12C inhibitors (i). We characterized frequencies of KRAS G12C mut and gene co-alt amon...